Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase II Study Evaluating the Efficacy of 90Yttrium-epratuzumab Tetraxetan Radioimmunotherapy in Adults With CD22+ Relapsed/Refractory B-ALL

NCT02844530 is registered in ClinicalTrials.gov with Nantes University Hospital as lead sponsor.

NCT NCT02844530
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02844530 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase II Study Evaluating the Efficacy of 90Yttrium-epratuzumab Tetraxetan Radioimmunotherapy in Adults With CD22+ Relapsed/Refractory B-ALL
Lead sponsor
Nantes University Hospital
Phase
Phase 2
Overall status
Withdrawn
Start date
Not reported
Completion date
January 31, 2017
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cd22+ relapsed/refractory b-all